Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis

Neves, Adriana Freitas; Araújo, Thaise Gonçalves; Biase, W. Karyna Freitas Santos; Meola, Juliana; Alcântara, Tânia Machado de; Freitas, Danielo G.; Goulart, Luiz Ricardo

doi:10.1016/j.clinbiochem.2008.06.013

Cited by 37 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A possible association may exist between AR polymorphisms and the development of prostate cancer (23). Another study also supported the hypothesis of increased AR mRNA levels being associated with the occurrence of prostate cancer (24)(25)(26).…”

Section: Brca1 Brca2 Ar and Igf-i Expression In Prostate Cancer: Cosupporting

confidence: 60%

BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: Correlation between RT-qPCR and immunohistochemical detection

Rabiau

Déchelotte²,

Adjakly³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. Identification and characterization of biomarkers in prostate cancer are important for improving the diagnosis. The aim of this study was to determine differences in the expression of 4 genes according to the stage of malignancy in prostate cancer. We analyzed BRCA1, BRCA2, androgen receptor (AR) and IGF-I gene expression in a cohort of 98 prostate biopsies. We used TaqMan RT-qPCR for mRNA detection, and correlation with proteins was performed using immunohistochemistry. Among the 98 studied prostate biopsies, high heterogeneity in the expression of the 4 genes was detected among the different histological types. However, down-regulation of BRCA1 and BRCA2 mRNA was detected, particularly in the normal tissues. The expression of AR was dependent on the stage of the tumor. The IGF-I gene was specifically expressed in the tumor tissues. Upon comparison between protein and mRNA expression for BRCA1, BRCA2 and AR, we obtained a trend; however, this did not achieve statistical significance. Regarding IGF-I, a correlation between mRNA expression and staining intensity of the protein was found to be significant (p<0.012). The AR biomarker was found to be slightly correlated with the prostate cancer diagnosis (p=0.013). AR was found to be decreased in the tumors with a 43% sensitivity and 90% specificity. The relative risk of 2.05 (1.13-3.69) indicated a 2-fold higher chance of cancer occurence when AR was ≤0.206.

show abstract

Section: Brca1 Brca2 Ar and Igf-i Expression In Prostate Cancer: Cosupporting

confidence: 60%

BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: Correlation between RT-qPCR and immunohistochemical detection

Rabiau

Déchelotte²,

Adjakly³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…No difference was found for expression levels of PCA3 and PSA genes alone, although for PCA3 the mean was higher in the PCa group. However, some studies have demonstrated significant differences between the expression levels of both genes in the urine of patients with PNH and PCa following prostatic massage (Hessels et al, 2003;Groskopf et al, 2006;Haese et al, 2008;Neves et al, 2008;Mearini et al, 2009;Jamaspishvili et al, 2011). Possibly this significance was not found in our study because these variables presented large dispersion and variability, which are reflected in the magnitude of the standard deviation.…”

Section: Discussioncontrasting

confidence: 50%

Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer

Coelho¹,

Guimarães²,

Cabral³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We evaluated the expression of the PCA3 gene in urine from patients with nodular hyperplasia/benign prostatic hyperplasia (PNH) or adenocarcinoma type prostate cancer (PCa).The study included 59 men: 22 with PCa, 26 with PNH, and 11 with no alterations (controls). Patients' urine was collected following prostatic massage and quantified by quantitative real-time PCR for prostate cancer antigen 3 gene (PCA3) and prostate-specific antigen gene (PSA) expression with the ACTB gene for normalization. PCA3 gene expression was detected in 16 patients with PCa and 4 with PNH; in the control group, there was no expression of the gene. No significant difference was observed in the mean levels of PCA3 and PSA expression, the PCA3/PSA ratio, and the total PSA levels when the groups of patients with PCa and PNH were compared. The area under the receiver operating characteristic (ROC) curve was 0.625, 0.596, 0.559, and 0.503 for PCA3 and PSA expression, the PCA3/PSA ratio, and total PSA levels, respectively. The sensitivity and specificity of the PCA3 test were 73 and 85%, respectively. Considering the estimated cutoff values (0.2219 and 0.5007 for PCA3 and PCA3/PSA, respectively), we observed a significant difference between the frequency of individuals with values above in the PCa group compared with the PNH group (P < 0.001). We conclude that the qualitative PCA3 test could be applied to initial screening for differentiation between individuals with PCa or PNH and those without prostate changes.

show abstract

“…Plusieurs études ont quantitativement évalué, par la technique de RT-PCR, l'expression du gène PCA3 dans des échantillons d'HBP. L'expression de PCA3 n'est pas constante : de 0 à 57 % des échantillons testés [36][37][38][39]. Elle a toujours été mesurée comme inférieure, de 5 à 66 fois, à celle observée dans les échantillons de cancer prostatique [8,22,[38][39][40][41][42].…”

Section: Le Test Urinaire Pca3 Dans Les éTats Pré-néoplasiques De La unclassified

Test urinaire PCA3, cancer de la prostate et autres pathologies prostatiques

Vlaeminck-Guillem

2012

Immuno-analyse & Biologie Spécialisée

View full text Add to dashboard Cite

Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis

Cited by 37 publications

References 29 publications

BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: Correlation between RT-qPCR and immunohistochemical detection

BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: Correlation between RT-qPCR and immunohistochemical detection

Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer

Test urinaire PCA3, cancer de la prostate et autres pathologies prostatiques

Contact Info

Product

Resources

About